Literature DB >> 5775632

Current concepts: the use of heparin.

D Deykin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5775632     DOI: 10.1056/NEJM196904242801706

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  The influence of drugs upon the anticoagulant activity of heparin.

Authors:  E D Hodby; J Hirsh; C Adeniyi-Jones
Journal:  Can Med Assoc J       Date:  1972-03-04       Impact factor: 8.262

2.  Monitoring heparin therapy with the activated partial thromboplastin time.

Authors:  R K Stuart; A Michel
Journal:  Can Med Assoc J       Date:  1971-03-06       Impact factor: 8.262

3.  Significane of intravascular coagulation in canine endotoxin shock.

Authors:  A H From; W W Spink; D Knight; H Gewurz
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

Review 4.  A synopsis of the clinical uses of argatroban.

Authors:  M Moledina; M Chakir; P J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2001-10       Impact factor: 2.300

5.  Management of pulmonary embolism.

Authors:  C V Ruckley
Journal:  Br Med J (Clin Res Ed)       Date:  1982-09-25

Review 6.  Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs?

Authors:  Jenneke Leentjens; Mike Peters; Anne C Esselink; Yvo Smulders; Cornelis Kramers
Journal:  Br J Clin Pharmacol       Date:  2017-07-09       Impact factor: 4.335

7.  A Retrospective Analysis of q12hr and q8hr Heparin for DVT/PE Prophylaxis in an Inpatient Rehabilitation Setting.

Authors:  Adam Dashner; Erin Siders PharmD
Journal:  J Pharm Technol       Date:  2022-05-10

8.  Control of heparin therapy.

Authors:  W R Pitney; J E Pettit; L Armstrong
Journal:  Br Med J       Date:  1970-10-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.